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Abstract: Specific immunotherapy (SIT) protocols for nutritional
allergens have only recently been established with a focus on oral
allergy syndrome because of pollen cross-reacting antibodies. For
these patients, a substantial number of studies have been published
suggesting benefits from SIT. The situation in true anaphylaxis to
food allergens such as peanut allergy is more complex, and
therapeutic strategies are based on individual protocols rather than
controlled studies. However, in defined cases, SIT represents a
promising approach for a durable protection from life-threatening
risks after accidental ingestion.
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Anaphylaxis to food is recognized as a common worldwideproblem, and its incidence seems to increase. In the past
years, investigations of allergic food proteins and immuno-
logic responses have provided new knowledge on strategies to
prevent food-induced anaphylaxis, one of them being the
allergen-specific immunotherapy (ASIT).1 In contrast to the
prevalent Bgold standard,[ the avoidance of the responsible
food, or the application of pharmacological regimens, which
target only the symptoms without affecting the allergic
pathogenesis, it represents the only curative and specific ap-
proach for type I allergy.2,3
MECHANISMS OF ASIT
The mechanisms by which the desensitizing effect is
achieved includes mainly the modulation of T cells and B cells,
especially by the generation of allergen-specific T-regulatory
cells leading to suppressed T-cell proliferation and an enhanced
Th1/Th0 cytokine response against the allergen. Specific
immunotherapy leads to an effective reduction of the threshold
for mast cell and basophil activation and to a significant in-
crease in allergen-specific immunoglobulin G4 (IgG4), IgG1,
and IgA, and a decrease in IgE in the late stage of the disease.4
As a result, successful ASIT does not only rise the allergen
concentration needed to induce immediate- or late-phase
reaction in the target tissue, but also diminishes the response
to nonspecific mucosal stimulation.5
PROBLEMS OF ASIT IN FOOD ANAPHYLAXIS
Although ASIT is a widely used immunomodulatory
treatment of different allergic diseases, for example, seasonal
allergic rhinitis, asthma, or insect venom hypersensitivity,
there are several problems concerning ASIT in food
anaphylaxis. In contrast to the diseases mentioned previously,
the clinical relevance is not given without restrictions. The
expression of food allergy varies with age, as for example, the
sensitization against cow’s milk’s (CM) protein or egg occurs
during the first 2 to 3 years of life, but is most likely to vanish
within adolescence.6 Because of this, the indication for SIT is
rather doubtful because avoidance of the responsible food is
often manageable.
However, there are situations where avoidance is not that
easily possible. Undeclared allergens in processed products
represent a major health problem for sensitized persons.
Peanut flour and gluten are known as potent food allergens.
When evaluated with enzyme-linked immunosorbent assay,
the hidden presence of gluten and peanut in Polish products
was detected in 4 (11.8%) of 34 processed foods (corn crisps,
wafers, cereal bar, and halva) and 5 (13.5%) of 37 foodstuffs
(cornflakes, corn crisps, bouillon cube, vegetable soup for
infants, curry powder) contained undeclared gluten.7,8 Until
recently, most food-control authorities were not in the position
to monitor hidden allergens and to take legal measures against
their presence in foodstuffs.9 Under this aspect, immunother-
apy would be a great benefit for peo- ple with severe
anaphylaxis after ingestion of the acclaimed products.
In addition to the theoretical difficulties in the indication
for ASIT therapy, there are major obstacles when it comes to
the correct realization of this treatment. This is mainly the lack
of standardized extracts from either native proteins or
recombinant allergens. Moreover, there are several essential
requirements that have to be guaranteed for the development of
safe and efficient ASIT vaccines such as the reproducible
clinical benefit, the lack of side effects, easy application, and a
good onset-to-clinical success ratio.2,4,10
PREVALENT USE OF ASIT ON FOOD ALLERGY
Standardized Schemes of ASIT in Pollen Allergy
and Pollen-Related Oral Allergy Syndrome
Pollen Allergy
The efficacy of ASIT in pollen allergy is already well
established.11 Besides the conventional standards for ASIT
with grass and tree pollen extracts like birch,12 alder, and
hazel, a new focus has been reported toward the establishment
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of ASIT to olive pollen. In the Mediterranean countries and
some areas of North America, allergy to Olea europaea pollen
is a major health problem.13 The prevalence of pollinosis
depends on the cultivation intensity and on the percentage of
sensitization to olive pollen in individuals with allergic rhinitis
varying from 15.2% in the Montpellier area14 to greater than
80% found in the southern Spanish province Jae´n.15,16 In
addition, severe anaphylactic reactions to pollen products such
as honey and jelly have been described recently.17Y19 Besides,
as the IgE-binding pattern of olive pollen is complex and
diverse, some olive allergens like Ole e 9 and Ole e10 also
exhibit IgE cross-reactivity with proteins from latex and
vegetable foods, such as tomato, kiwi, potato, and peach.20,21
Patients with allergies to these materials would benefit from
ASIT against olive pollen, which is already the current
standard of treatment to induce hyporesponsiveness by
applying injections of increasing amounts of allergen
extracts.22,23 Although the use of ASIT with standardized
olive pollen extracts is considered to be an effective method to
reduce symptoms of a type-I allergic reaction, there is still the
risk of adverse reactions because of the high diversity of the
allergenic components of olive pollen. Among them, 10
different allergens have been characterized by now,24 and it
seems to be an important deficiency in the current standardi-
zation methods, that the amount and affinity of individual IgE
antibodies directed against a particular allergen, either major
or minor, are not adequately taken into account. A solution to
increase the safety of allergen vaccines could be the reduction
of minor allergen content,15 and for prevention of allergic
reactions, a prophylactic intranasal treatment with recombi-
nant allergen fragments might be a promising attempt.25
However, further studies will be required to assess new
strategies and to fully determine the underlying mechanisms.
Pollen-Related Oral Allergy Syndrome
Specific immunotherapy is not only an established
method used in pollen-induced allergies, but also in pollen-
related allergic reactions to nonpollen products. Up to 70% of
individuals with pollen allergy perceive symptoms like
immediate itching in mouth and throat or mild-to-moderate
angioedema after ingestion of fresh fruits of the Rosaceae
family, nuts, or vegetables, also referred to as the oral allergy
syndrome (OAS).26,27 This phenomenon is caused by cross-
reactive IgE antibodies that recognize homologous allergens
in birch pollen and fruits,28Y30 the primary sensitizer being
the major birch pollen allergen Bet v 1. Its fruit homologues
are more liable and sensitive to processing in the stomach
and therefore lack sensitization directly. Selective recognition
of epitopes on fruit or vegetable homologues of Bet v 1 are
found to be extremely rare,31 so that the spectrum of IgE
specificities is broadest against the pollen allergen. Taking
these aspects into account, several studies have investigated
the effect of ASITwith tree pollen on OAS. It has been a long-
standing debate whether immunotherapy for inhalant allergies
indeed has a beneficial effect on associated food allergies, but
despite some studies with limited effect/negative results,32,33
a positive impact has been demonstrated in most cases, with
improvement of the OAS from 50% up to a complete loss of
symptoms in subjects with monosensitized birch pollen al-
lergy confronted by an open apple challenge.34 Reasons for
the different outcomes might be the high dose dependence
of the effect of ASIT and a strong difference in the concentra-
tion of the major allergen Bet v 1 in the commercial extracts
or the existence of other less well-defined cross-reactive
allergens, which are not present or sufficiently enough in
the birch pollen extracts.35 According to these findings, further
studies will be required to determine whether the most
effective treatment of OAS can be achieved using ASIT with
corecognized inhalant allergens or through cotreatment with
purified pollen-related food allergens to guarantee a long-
lasting effect.36
Individual Schemes of SIT
CM Allergy
In contrast to the standardized schemes of SIT for
pollen-induced and pollen-related allergies mentioned pre-
viously, in certain food allergies, individually adapted schemes
have to be applied. Especially in protein allergy, like CM
allergy in young children with atopic eczema, the variable
response of each patient to the different allergen components
may influence the potential clinical outcome. Therefore, the
mode of application of ASIT is a very delicate matter and not
seldom has to be interrupted and discontinued because of the
occurrence of uncontrolled side effects that might indicate
possible differences in the mechanism, which are known for
classical immunotherapy with airway allergies. With respect to
the fact that prolonged elimination diets are not without risks,
such as deficiency and growth retardation,37 eating disorders,
impaired psychosocial development,38,39 or even severe
anaphylactic reactions,40 SIT has become a successfully
used alternative, the major aim of which is not to alter the
cause of food allergy, but to induce a tolerance toward the
incriminated food and to increase the threshold dose to elicit
allergic symptoms in case of continuous exposure. One
current scheme for CM desensitization is to administer
increasing amounts of CM starting from 1 drop of whole
CM diluted 1:25 with water corresponding to approximately
0.06 mg of CM protein. Afterward, the doses are doubled first
every 7 days until day 70, then subsequently every 16 days,
until a daily intake of 200 mL is achieved (normally in about 6
months).41 Besides, there are many different proposals how to
receive successful results,42,43 their optimal adaptation for
each individual patient probably being the best way to
guarantee an effective clinical outcome. However, these
schemes of daily application differ from the classical way of
ASIT. To allow exposure to a gradually escalating dose of a
specific allergen to decrease allergic and inflammatory
responses, a buildup phase with once weekly applications is
followed by a maintenance phase with monthly repetitions that
has to be continued for several, normally 3 to 5, years.44 Daily
application requires far more compliance of the patient and
thus might bear a higher risk of adverse reactions if interrupted
for some days. To most, applying these schemes is a very time-
consuming procedure and demands discipline and experience.
Despite previous tolerance, on reexposure to the allergen,
moderate systemic reactions might easily occur if a certain
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maintenance dose is not guaranteed.45 Oral tolerance induc-
tion by ASIT in CM allergy is therefore not to be regarded
without limitations and has to be discussed individually for
each patient.
Nonstandardized/Experimental Approaches
The current information on custom-made protocols for
ASIT in severe food anaphylaxis is rather scarce. In cases in
which avoidance is not possible, ASIT should, however, be
considered. Most of the data come from approaches in severe
peanut allergy, which is associated to life-threatening
symptoms to a high degree. Although ASIT in peanut allergy
has been considered extremely difficult, there are several
reports encouraging this strategy.46Y48 We have undertaken
an individualized ASIT approach to an adult patient with
severe kiwi anaphylaxis who was effectively desensitized by a
sublingual extract from fresh kiwi pulp. Although the whole
procedure is extremely time consuming as one might have to
start with a concentration of one tenth of the lowest positive
concentration in skin prick test,49 recent findings could
demonstrate the efficacy and long-lasting protective effect of
the applied ASIT.50 This effect was also paralleled by a sub-
stantial induction of kiwi-specific IgG4.11
In the future, the use of specific IgE antibodies such as
omalizumab could be an interesting point of research to reduce
the occurrence of adverse systemic reactions in immunother-
apy. Some recently published studies outline the positive
effects of the monoclonal anti-IgE antibody as a pretreatment
in peanut allergy,51 rush immunotherapy for ragweed-induced
seasonal allergic rhinitis,52 or in injection immunotherapy
with a moderate dose of house dust mite extract in house
dustYsensitive adults with atopic eczema.53
In addition, new genetically engineered major allergens
from food sources will enable better standardized and hope-
fully better tolerable protocols.
CONCLUSION
Taken together, immunotherapy in food anaphylaxis is a
possible option but not always easily applicable because of the
risk of side effects. Several standard schemes exist for pollen-
induced and pollen-related food allergy, but still for some
products, such as CM or peanut, individual procedures have to
be applied to guarantee a successful tolerance induction. Even if
only a few studies allow assumption of a generally long-lasting
protective effect of ASIT by now, the results provided up to now
are quite encouraging.54 To guarantee a safer and more
convenient use of ASIT in the future, more studies will be
necessary.
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